MPP participated in the 12th IAS Conference on HIV Science that took place in Brisbane, Australia and virtually from 23 to 26 July 2023. IAS 2023 shined a spotlight on the world’s advances in HIV research.
Please see below MPP’s in-person participation in some key sessions on Sunday 23 July 2023 and Tuesday 25 July 2023:
MPP’s Head of Scientific and Medical Affairs, Lobna Gayeeb, spoke in the Satellite Session “Advancing HIV care for mothers and newborns: Exploring long-acting solutions”.
MPP’s Policy and Advocacy Manager, Sébastien Morin, presented on “Access to CAB-LA for PrEP: Update on licensing and outlook for Asia” in the Satellite Session “Preparing for the introduction of injectable cabotegravir for HIV prevention in Asia”.
He also presented at the Regional networking event for IAS Members from Latin America and the Caribbean, on “Acceso a CAB-LA para PrEP: Actualización sobre licencias y perspectivas para la región LAC”.
Also presented at #IAS2023, our latest publication with the Journal of the International AIDS Society (JIAS) supplement,“Advancing use of long-acting and extended delivery (LAED) HIV prevention and treatment regimens” by Medicines Patent Pool co-authors on voluntary licensing of long-acting HIV prevention and treatment regimens: using a proven collaboration- and competition-based mechanism to rapidly expand at-scale, sustainable, quality-assured and affordable supplies in LMICs.
Click Here To Access The Paper
Press and Media
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to and facilitate the development of life-saving medicines for low- and middle-income countries. Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups, and other stakeholders to prioritise and license needed medicines and pool intellectual property to encourage generic manufacture and the development of new formulations.
To date, MPP has signed agreements with 22 patent holders for 13 HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals, a tuberculosis treatment, a cancer treatment, four long-acting technologies, a post-partum haemorrhage medicine, three oral antiviral treatments for COVID-19 and 16 COVID-19 technologies.
MPP was founded by Unitaid, which continues to be MPP’s main funder. MPP’s work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC), Government of Canada, the World Intellectual Property Organization (WIPO) and the Government of Flanders. MPP’s activities in COVID-19 are undertaken with the financial support of the Japanese Government, the French Ministry for Europe and Foreign Affairs, the German Agency for International Cooperation, and SDC.